menu
    • menu
    [{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"RBN-2397","moa":"ionotropic non-NMDA glutamate receptors (AMPA and\/or KA receptors); poly-ADP-ribose polymerase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ribon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ribon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"RBN-2397","moa":"ionotropic non-NMDA glutamate receptors (AMPA and\/or KA receptors); poly-ADP-ribose polymerase inhibitors","graph1":"Oncology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ribon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"RBN-2397","moa":"||ionotropic non-NMDA glutamate receptors (AMPA and\/or KA receptors); poly-ADP-ribose polymerase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ribon Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Ribon Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Ribon Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RBN-2397","moa":"||ionotropic non-NMDA glutamate receptors (AMPA and\/or KA receptors); poly-ADP-ribose polymerase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ribon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ribon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"RBN-2397","moa":"ionotropic non-NMDA glutamate receptors (AMPA and\/or KA receptors); poly-ADP-ribose polymerase inhibitors","graph1":"Oncology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ribon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"RBN-2397","moa":"ionotropic non-NMDA glutamate receptors (AMPA and\/or KA receptors); poly-ADP-ribose polymerase inhibitors","graph1":"Oncology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ribon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"RBN-2397","moa":"ionotropic non-NMDA glutamate receptors (AMPA and\/or KA receptors); poly-ADP-ribose polymerase inhibitors","graph1":"Oncology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Ribon Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RBN-3143","moa":"PARP-14","graph1":"Dermatology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ribon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RBN-3143","moa":"PARP-14","graph1":"Dermatology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ribon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RBN-3143","moa":"PARP-14","graph1":"Dermatology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ribon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ribon Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Ribon Therapeutics \/ Boehringer Ingelheim GmbH"}]

    Find Clinical Drug Pipeline Developments & Deals by Ribon Therapeutics

    Menu

    Ribon Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ribon Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Ribon Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RBN-3143

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ribon Therapeutics Doses First Patient in Phase 1 Clinical Study with RBN-3143 in Patients with Moderate-to-Se...

                            Details : RBN-3143, a first-in-class, oral small molecule inhibitor of PARP14 which leads to a decrease in alarmins and dampening of the IL-17 and IL-4/13 signaling pathways. It is being developed for moderate-to-severe atopic dermatitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 09, 2023

                            Lead Product(s) : RBN-3143

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ribon Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Ribon Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RBN-2397,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : $25.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Ribon Therapeutics Announces $25 Million Equity Investment from Pfizer

                            Details : Ribon plans to use the proceeds to support clinical development of its potentially first-in-class oral small molecule programs in oncology (RBN-2397, a PARP7 inhibitor) and immunology (RBN-3143, a PARP14 inhibitor).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 30, 2023

                            Lead Product(s) : RBN-2397,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : $25.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ribon Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Ribon Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim

                            Details : Boehringer Ingelheim aims to develop novel therapies based on Ribon’s CD38 program to transform the lives of patients with immunological and fibrotic diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 29, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ribon Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Ribon Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RBN-3143

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ribon Therapeutics Announces Late-Breaking Presentation of Preclinical Data on RBN-3143 at the European Respir...

                            Details : RBN-3143, a first-in-class, orally administered, small molecule inhibitor of PARP14, has the potential to be a differentiated therapy for the treatment of numerous inflammatory diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 06, 2022

                            Lead Product(s) : RBN-3143

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ribon Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Ribon Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RBN-2397,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ribon Therapeutics Announces Initiation of Phase 1b/2 Study of RBN-2397 in Combination with Pembrolizumab in P...

                            Details : RBN-2397 is an orally available small molecule inhibitor of PARP7 being developed for the treatment cancer. RBN-2397 has been shown to directly inhibit cellular proliferation and restore interferon signaling to stimulate an innate and adaptive antitumor ...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 29, 2022

                            Lead Product(s) : RBN-2397,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ribon Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Ribon Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RBN-3143

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SAD/MAD Safety and PK Study of RBN-3143 in Healthy and Atopic Dermatitis Subjects

                            Details : RBN-3143 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 31, 2022

                            Lead Product(s) : RBN-3143

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ribon Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Ribon Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RBN-2397

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RBN-2397 in Combination With Pembrolizumab in Patients With SCCL

                            Details : RBN-2397 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 19, 2021

                            Lead Product(s) : RBN-2397

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ribon Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Ribon Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RBN-2397

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Ono Pharmaceutical

                            Deal Size : $148.3 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Ribon Therapeutics Inks License Agreement with Ono Pharmaceutical for RBN-2397

                            Details : Ono will have the exclusive rights to develop and commercialize RBN-2397 in the Ono Territory. Additionally, Ono will have the right to participate in global clinical studies of RBN-2397 by bearing the costs of such studies in the Ono Territory.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $16.3 million

                            February 02, 2021

                            Lead Product(s) : RBN-2397

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Ono Pharmaceutical

                            Deal Size : $148.3 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Ribon Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Ribon Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RBN-2397

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ribon Therapeutics to Present New Preclinical Data on its PARP7 Inhibitor - RBN-2397 - and its Discovery Platf...

                            Details : RBN-2397 restores type I IFN signaling in the tumor, causes complete tumor regressions and adaptive immunity in preclinical models.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 15, 2020

                            Lead Product(s) : RBN-2397

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ribon Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Ribon Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RBN-2397

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ribon Therapeutics to Present New Preclinical Data at the Upcoming AACR Virtual Annual Meetings

                            Details : This presentation will highlight 3 ongoing clinical activities of the company which includes data on a selective PARP14 Inhibitor and RBN-2397 in Treatment of cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 14, 2020

                            Lead Product(s) : RBN-2397

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth